{"id":"W4311746946","doi":"10.1093/ofid/ofac492.109","title":"1586. Phase 3/3b Experience with Long-Acting Cabotegravir and Rilpivirine: Efficacy and Safety Outcomes Through Week 96 by Race","year":2022,"lang":"en","type":"article","venue":"Open Forum Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"Regeneron Pharmaceuticals; Gilead Sciences; Moderna; Pfizer; Eli Lilly and Company","keywords":"Rilpivirine; Medicine; Regimen; Human immunodeficiency virus (HIV); Internal medicine; Viral load; Antiretroviral therapy; Virology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006911359,0.0004797765,0.001090355,0.0002593206,0.0003806228,0.0007176176,0.0004253798,0.000535658,0.005644397],"category_scores_gemma":[0.003126882,0.0002910993,0.001843878,0.0004956023,0.0004335098,0.0008153951,0.0005892327,0.001081707,0.001267509],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004058623,"about_ca_system_score_gemma":0.001424016,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001038301,"about_ca_topic_score_gemma":0.001757262,"domain_scores_codex":[0.9979489,0.001308198,0.0001599119,0.0002082408,0.0002040916,0.0001706404],"domain_scores_gemma":[0.9979836,0.0004526629,0.0006408889,0.000242388,0.0002934174,0.0003871296],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7992616,0.009086134,0.03902485,0.001045833,0.004340756,0.0000611351,0.0003108581,0.0009301002,0.01528121,0.0002448036,0.005939043,0.1244737],"study_design_scores_gemma":[0.2603323,0.4908452,0.2073724,0.0003173806,0.007204365,0.0002411467,0.000400402,0.001290543,0.01177395,0.0006109194,0.01950565,0.0001057493],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9810467,0.004189123,0.001218889,0.0003505172,0.00009941607,0.002275944,0.006027242,0.00008874943,0.004703366],"genre_scores_gemma":[0.9846139,0.0008826336,0.001892192,0.0006537425,0.0001140219,0.003667434,0.004956536,0.0000436048,0.003176083],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006911359,"threshold_uncertainty_score":0.03655118,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0135506882634918,"score_gpt":0.3114046751923415,"score_spread":0.2978539869288497,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}